FindTrial
Sign In

EVALUATION OF THE EFFECT OF ADDING GNRH AGONIST TO THE DUAL PROGESTERONE (INTRAMUSCULAR AND VAGINAL) AS LUTEAL PHASE SUPPORT IN FROZEN-THAWED EMBRYO TRANSFERS DURING ARTIFICIAL CYCLES: A RANDOMIZED CONTROLLED TRIAL.

Evaluation of the effect of Adding Single-dose Gonadotrophins Releasing Hormone Agonist for Luteal Phase Support in frozen embryo transfer in antagonist IVF/ICSI cycles.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/09/036421
Enrollment
120
Registered
2021-09-10
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N979- Female infertility, unspecified

Interventions

Intervention1: GnRH agonist: GnRH agonist (0.1mg subcutaneous injection on day of embryo transfer)- 1 day, Progesterone (180mg/day intra-vaginally) till the positive Beta-HCG test(15 days) and 50mg/da

Sponsors

Angels Fertility Center
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: a.Patients undergoing IVF/ICSI cycles using FET. b. Age between 20 to 40 years. c. Antagonist cycles d. Given P4 and E2 or P4, E2 plus GnRH agonist as LPS. e. Written informed consent.

Exclusion criteria

Exclusion criteria: a. Uterine fibroid if encroaching uterine cavity. b. Mullerian anomalies. c. Ovarian endometrioma. d. Polycystic ovarian syndrome (PCOS). e. Use of donor sperms or oocytes. f. Adnexal hydrosalpinx "except after disconnection". g. Allergy to triptorelin.

Design outcomes

Primary

MeasureTime frame
1. To determine Biochemical Pregnancy (Positive urine test or serum Ã?²-HCG50m IU/ml after 14 days of embryo transfer). 2. To determine Clinical Pregnancy Rate (Presence of gestational sac or fetus heartbeat at 4-weeks after embryo transfer or 6-7 weeks or pregnancy). 3. To determine implantation rate (Number of gestational sacs divided by the number of embryos transferred). 4. To determine Ongoing Pregnancy Rate (Pregnancy contouring beyond 12 weeks of pregnancy).Timepoint: 1. To determine Biochemical Pregnancy (Positive urine test or serum Ã?²-HCG50m IU/ml after 14 days of embryo transfer). 2. To determine Clinical Pregnancy Rate (Presence of gestational sac or fetus heartbeat at 4-weeks after embryo transfer or 6-7 weeks or pregnancy). 3. To determine implantation rate (Number of gestational sacs divided by the number of embryos transferred). 4. To determine Ongoing Pregnancy Rate (Pregnancy contouring beyond 12 weeks of pregnancy).—

Secondary

MeasureTime frame
To determine the incidence of OHSSTimepoint: Continious monitoring during the study.;To determine the Miscarriage Rate.Timepoint: Upto 10 weeks of gestation;To determine the Multiple Pregnancy RateTimepoint: Pregnancy with 2/more fetuses;To determine the role of GnRH agonist as LPS agent in FET antagonist IVF/ICSI cycles based on womens age and duration of infertility.Timepoint: At the end of the study.—

Countries

India

Contacts

Public ContactMohd Abdul Khader

Bhaskar Pharmacy College, Angels Fertility Center

talhajabeen9191@gmail.com7995906525

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026